Tesis Biosciences acquires Genome Explorations to accelerate clinical research and product development for the treatment of chronic diseases

0

PHOENIX and MEMPHIS, Tenn., February 16, 2022 /PRNewswire/ — Tesis Biosciencesthe leader in targeted genetic sequencing, acquired Genome Explorations, a leading research institution providing global genomic profiling and molecular diagnostic services.



The acquisition, which aligns with Tesis Biosciences’ increased focus on clinical research and product development, will enable Tesis to accelerate the completion of a therapeutic clinical initiative that could lead to the market for a proprietary product in early 2022, awaiting authorisation.


Genome explorations serves academic centers, the pharmaceutical and biotechnology industry, oncologists and pathologists with innovative diagnostic, prognostic, predictive and personalized tests. Its highly trained clinical and research staff, who focus on global genomic profiling and molecular diagnostic services, will complement and augment Tesis’ in-house research staff to accelerate the development of proprietary products that will transform the way chronic diseases are processed.


“We have a number of proprietary clinical initiatives that this acquisition allows us to complete by integrating ongoing research data from Genome Explorations with Tesis,” said Tesis’ CEO. Ron King. By enabling clinicians to individualize treatment for people with cancer and other chronic diseases, we can improve the quality of life for millions of Americans and revolutionize medicine.”


Six out of 10 in the United States adults have at least one chronic condition – such as cancer, heart disease, lung disease or diabetes – while four in 10 have at least two chronic conditions.


With its genetically integrated medical platform for targeted genetic sequencing and comprehensive genetic data collection, Tesis Biosciences is fueling advances in chronic disease management. The company currently operates laboratories in Arizona, Colorado and Texas.


“The merger of our genomics research staff and clinical facilities with Tesis Biosciences will accelerate the discovery of genetic treatments for chronic disease management and prevention,” said Dr. Divyen Patel, Founder and President of Genome Explorations. “This collaboration will result in better outcomes and improved lives for our patients.”


About Tesis Biosciences
Tesis Biosciences’ genetically integrated medical platform has revolutionized targeted genetic sequencing. Our mission is to change medicine by providing doctors, hospitals and researchers with the tools to help patients treat and overcome major chronic diseases such as heart and lung disease, cancer and Alzheimer’s disease through to advanced genetic testing. Tesis offers healthcare providers and physicians access to our unique genetic testing and precision medicine, enabling them to create personalized care plans for the treatment of chronic conditions – individually and across generations. We also enable medical device and pharmaceutical companies to bring new products to market and create a robust repository of genetic data and research. Visit www.tesisbiosciences.com to learn more.


About Genome Explorations Inc
Genome Explorations Inc. was founded by Dr. Divyen H. Patel to provide academic and industrial institutes with a comprehensive genotyping and gene expression profiling solution. Dr. Patel initiated and led the Affymetrix GeneChip Treatment Core at St. Jude Children’s Research Hospital. The results of one of the many studies conducted on its nucleus were described in a fundamental study on the cover of Cancer Cell. The study showed for the first time that microarray technology could be used to improve the diagnosis of pediatric leukemia and could also be used to assess prognostic outcomes. The vast experience gained from working with dozens of researchers on many varied projects has made Genome Explorations Inc. a major source of Affymetrix services for researchers around the world for the past six years. Genome Explorations is also a licensed Combimatrix chip service provider. Genome Explorations has worked with over 250 academic researchers and over 75 companies to provide gene expression and genotyping services. Visit genome-explorations.com to learn more.


Media Contact:

Kim Warth
Amendola Communications
303-918-9205
[email protected]



Quote Show original content to download multimedia:https://www.prnewswire.com/news-releases/tesis-biosciences-acquires-genome-explorations-to-accelerate-clinical-research-and-product-development-for-chronic-disease-cures-301483118.html


SOURCE Tesis Biosciences

Share.

Comments are closed.